DOCSLIB.ORG

2019.11 REPUBLICAN LIST of Narcotic Drugs, Psychotropic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019.11 REPUBLICAN LIST of Narcotic Drugs, Psychotropic See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/337290110 2019.11 REPUBLICAN LIST of narcotic drugs, psychotropic substances and their precursors which are subject to the state control in the Republic of Belarus (Russian-English version w... Experiment Findings · November 2019 DOI: 10.13140/RG.2.2.23721.34400 CITATIONS 0 1 author: Alexander Nevero State Forensic Examination Committee of the Republic of Belarus 19 PUBLICATIONS 172 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Anti-drug legislation of the Republic of Belarus View project All content following this page was uploaded by Alexander Nevero on 15 November 2019. The user has requested enhancement of the downloaded file. 2019.11 РЕСПУБЛИКАНСКИЙ ПЕРЕЧЕНЬ наркотических средств, психотропных веществ и их прекурсоров, подлежащих государственному контролю в Республике Беларусь (русско-английская версия со структурными формулами) REPUBLICAN LIST of narcotic drugs, psychotropic substances and their precursors, which are subject to the state control in the Republic of Belarus (Russian-English version with structural formulas) The English translation is not official The Official Russian version is available here In case of any discrepancy or ambiguity between the English version and the Russian version and in case of any disputes, the Official Russian version shall prevail This translation was prepared by Alexander Nevero with the participation of Catherine Zavizion Минск Ноябрь 2019 Minsk November 2019 1 СПИСОК ИСПОЛЬЗОВАННЫХ ПРАВОВЫХ АКТОВ LIST OF USED LEGAL ACTS Закон Республики Беларусь от 13.07.2012 № 408-З "О наркотических средствах, психотропных веществах, их прекурсорах и аналогах" Law of the Republic of Belarus of 13.07.2012 № 408-Z "On narcotic drugs, psychotropic substances, their precursors and analogues" Декрет Президента Республики Беларусь от 28.12.2014 № 6 "О неотложных мерах по противодействию незаконному обороту наркотиков" Decree of the President of the Republic of Belarus of 28.12.2014 № 6 "On urgent measures on counteraction to illicit drug trafficking" Закон Республики Беларусь от 16.07.2016 № 404-З "О внесении изменений и дополнений в некоторые законы Республики Беларусь по вопросам противодействия незаконному обороту наркотических средств, психотропных веществ, их прекурсоров и аналогов" Law of the Republic of Belarus of 16.07.2016 № 404-Z "On amendments and additions to some laws of the Republic of Belarus on counteraction to illicit trafficking of narcotic drugs, psychotropic substances, their precursors and analogues" Постановление Совета Министров Республики Беларусь от 09.09.2019 № 606 "Об установлении крупного размера наркотических средств, психотропных веществ либо их прекурсоров или аналогов" Resolution of the Council of Ministers of the Republic of Belarus of 09.09.2019 № 606 "On the establishment of a large size of narcotic drugs, psychotropic substances, their precursors or analogues" Официальный сайт Министерства внутренних дел Республики Беларусь. Химические вещества, относящиеся к аналогам наркотических средств, психотропных веществ The official website of the Ministry of Internal Affairs of the Republic of Belarus. Chemical substances which are analogues of the narcotic drugs and psychotropic substances Постановление Государственного комитета судебных экспертиз Республики Беларусь от 19.02.2015 № 2 "Об установлении перечня заместителей атомов водорода в структурных формулах наркотических средств, психотропных веществ или базовых структурах" Resolution of the State Forensic Examination Committee of the Republic of Belarus of 19.02.2015 № 2 "On the establishment of the List of substituents of hydrogen atoms in the structural formulas of the narcotic drugs, psychotropic substances or base structures" Постановление Государственного комитета судебных экспертиз Республики Беларусь от 02.12.2015 № 10 "О внесении дополнений в постановление Государственного комитета судебных экспертиз Республики Беларусь от 19 февраля 2015 г. № 2" Resolution of the State Forensic Examination Committee of the Republic of Belarus of 02.12.2015 № 10 "On additions to the Resolution of the State Forensic Examination Committee of the Republic of Belarus of February 19, 2015 № 2" Постановление Министерства здравоохранения Республики Беларусь от 11.02.2015 № 19 "Об установлении Республиканского перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих государственному контролю в Республике Беларусь" Resolution of the Ministry of Health of the Republic of Belarus of 11.02.2015 № 19 "On the establishment of the Republican List of narcotic drugs, psychotropic substances and their precursors which are subject to the state control in the Republic of Belarus" Постановление Министерства здравоохранения Республики Беларусь от 25.11.2015 № 112 "О внесении изменений и дополнений в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 25.11.2015 № 112 "On amendments and additions to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 25.01.2017 № 10 "О внесении изменений и дополнений в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 25.01.2017 № 10 "On amendments and additions to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 29.03.2017 № 28 "О внесении дополнений и изменения в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 29.03.2017 № 28 "On additions and amendment to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 11.08.2017 № 82 "О внесении дополнения в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 11.08.2017 № 82 "On addition to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 30.11.2017 № 105 "О внесении дополнений и изменения в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 30.11.2017 № 105 " On additions and amendment to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 27.04.2018 № 37 "О внесении дополнений и изменений в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 27.04.2018 № 37 "On additions and amendments to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 07.12.2018 № 91 "О внесении дополнений и изменения в постановление Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 07.12.2018 № 91 "On additions and amendment to the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 05.07.2019 № 68 "Об изменении постановления Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 05.07.2019 № 68 "On amendment of the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Постановление Министерства здравоохранения Республики Беларусь от 11.11.2019 № 100 "Об изменении постановления Министерства здравоохранения Республики Беларусь от 11 февраля 2015 г. № 19" Resolution of the Ministry of Health of the Republic of Belarus of 11.11.2019 № 100 "On amendment of the Resolution of the Ministry of Health of the Republic of Belarus of February 11, 2015 № 19" Авторы выражают искреннюю благодарность Владимиру Мелкозерову (Екатеринбург, Российская Федерация) за неоценимую консультативную помощь и постоянную поддержку при подготовке данных материалов The authors express their sincere gratitude to Vladimir Melkozerov (Ekaterinburg, Russian Federation) for the invaluable advice and constant support in the preparation of these materials 2 STRU CTU RE O F TH E RE PUB LICA N LIST СТРУКТУРА РЕСПУБЛИКАНСКОГО ПЕРЕЧНЯ STRUCTURE OF THE REPUBLICAN LIST NAR CO TIC D RUG S БАЗОВАЯ СТРУКТУРА НАРКОТИЧЕСКИЕ СРЕДСТВА СПИСОК 1 СПИСОК 2 СПИСОК 3 СПИСОК 4 СПИСОК 5 BASE STRUCTURE NARCOTIC DRUGS SCHEDULE 1 SCHEDULE 2 SCHEDULE 3 SCHEDULE 4 SCHEDULE 5 НАРКОТИЧЕСКИЕ СРЕДСТВА, НЕ ВКЛЮЧЕННЫЕ В ГРУППЫ NARCOTIC DRUGS NOT INCLUDED IN GROUPS 13 + 4 6 8 31 N0 1 . M O RPHIN AN S NH Н01 МОРФИНАНЫ [базовая структура – морфинан] N01 MORPHINANS [base structure – morphinan] 21 4 25 N02. 7,8-DIDE HYD RO M O RPHI NA NS NH Н02 7,8-ДИДЕГИДРОМОРФИНАНЫ [базовая структура – 7,8-дидегидроморфинан] N02 7,8-DIDEHYDROMORPHINANS [base structure – 7,8-didehydromorphinan] 13
Load more

Recommended publications
  • 3. 4 Ketamina E Analoghi
    NEW DRUGS Nuove Sostanze Psicoattive 3. 4 Ketamina e analoghi 765 766 NEW DRUGS Nuove Sostanze Psicoattive Ketamina Nome Ketamina; (Ketamine) Struttura molecolare O NH CH3 Cl Formula di struttura C13H16ClNO Numero CAS 6740-88-1 (base libera) / 1867-66-9 (sale cloridrato) Nome IUPAC 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one Altri nomi (±)-2-(2-chlorophenyl)-2-methylamino)cyclohexanone; (±)-2-(o-chlorophenyl)-2-methylamino)cyclo hexanone; 2-(methylami- no)-2-(2-chlorophenyl)cyclohexanone; 2-(methylamino)-2-(o-chlorophenyl) cyclohexanone; (±)-Ketamine; CI-581; CL-369; CN- 52,372-2. Nomi commerciali (per uso umano o veterinario): Esketamie; Ketalar base; Ketamine Base; Ketavet; Ketolar; Vetalar Ketalar, Ketamine Panpharma, Ketanest-S; Ketalar, Ketaminol; Vetalar Vet., Ketaminol Vet.; Clorketam, Imalgene, Anesketin, Ketamine Ceva, Narketan, Ketaset, Anesketin. Nomi gergali: K, special K, kit kat, tac et tic, cat valium, vitamin K, ket, super K, Kaddy, Kate, Ket, Kéta K, Jet, Super acid, 1980 acid, Special LA coke, Super C, Purple, Mauve, Green. Peso molecolare 237.725 g/mol Aspetto Polvere/cristalli bianchi. Punto di fusione della ketamina base libera: 92-93 °C; del cloridrato: 262-263°C. Informazioni generali La ketamina è una arilcicloalchilamina strutturalmente correlata alle ciclidine quali ad esempio l’etilciclidina, la fenciclidina, la roliciclidina e la tenociclidina. La ketamina è una molecola di origine sintetica, sintetizzata nel 1962, brevettata in Belgio nel 1963. E’ stata progettata nell’ambito della ricerca di analoghi strutturali delle cicloesilamine a cui appartiene anche la fenciclidina (PCP). La ketamina ha proprietà anestetiche ed analgesiche. E’ ampiamente utilizzata in ambito veterinario, molto meno come anestetico nell’uomo.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • Moves to Amend HF No. 2711 As Follows
    05/05/20 ​ REVISOR KLL/JK A20-0767​ 1.1 .................... moves to amend H.F. No. 2711 as follows:​ 1.2 Delete everything after the enacting clause and insert:​ 1.3 "ARTICLE 1​ 1.4 APPROPRIATIONS​ 1.5 Section 1. APPROPRIATIONS.​ 1.6 The sums shown in the column under "APPROPRIATIONS" are added to or reduce the​ 1.7 appropriations in Laws 2019, First Special Session chapter 5, to the agencies and for the​ 1.8 purposes specified in this article. The appropriations are from the general fund, or another​ 1.9 named fund, and are available for the fiscal year indicated for each purpose.​ 1.10 APPROPRIATIONS​ 1.11 Available for the Year​ 1.12 Ending June 30​ 1.13 2020​ 2021​ 1.14 Sec. 2. CORRECTIONS​ 1.15 Subdivision 1. Total Appropriation​ $​ 205,000​ $​ 5,545,000​ 1.16 The amounts that may be spent for each​ 1.17 purpose are specified in the following​ 1.18 subdivisions.​ 1.19 Subd. 2. Correctional Institutions​ -0-​ (2,545,000)​ 1.20 To account for overall bed impact savings of​ 1.21 reductions in the penalties for controlled​ 1.22 substances offenses involving the possession​ 1.23 of marijuana, investments in community​ 1.24 supervision, and increased penalties for sex​ 1.25 trafficking offenses, the fiscal year 2021​ Article 1 Sec. 2.​ 1​ 05/05/20 ​ REVISOR KLL/JK A20-0767​ 2.1 appropriation from Laws 2019, First Special​ 2.2 Session chapter 5, article 1, section 15,​ 2.3 subdivision 2, is reduced by $2,545,000.​ 2.4 Subd.
    [Show full text]
  • Texas Controlled Substances Act
    HEALTH AND SAFETY CODE TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES CHAPTER 481. TEXAS CONTROLLED SUBSTANCES ACT SUBCHAPTER A. GENERAL PROVISIONS Sec.A481.001.AASHORT TITLE. This chapter may be cited as the Texas Controlled Substances Act. Acts 1989, 71st Leg., ch. 678, Sec. 1, eff. Sept. 1, 1989. Sec.A481.002.AADEFINITIONS. In this chapter: (1)AA"Administer" means to directly apply a controlled substance by injection, inhalation, ingestion, or other means to the body of a patient or research subject by: (A)AAa practitioner or an agent of the practitioner in the presence of the practitioner; or (B)AAthe patient or research subject at the direction and in the presence of a practitioner. (2)AA"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of a carrier or warehouseman acting in the usual and lawful course of employment. (3)AA"Commissioner" means the commissioner of state health services or the commissioner 's designee. (4)AA"Controlled premises" means: (A)AAa place where original or other records or documents required under this chapter are kept or are required to be kept; or (B)AAa place, including a factory, warehouse, other establishment, or conveyance, where a person registered under this chapter may lawfully hold, manufacture, distribute, dispense, administer, possess, or otherwise dispose of a controlled substance or other item governed by the federal Controlled Substances Act (21 U.S.C.
    [Show full text]
  • Moves to Amend HF No. 2128 As Follows:​ Delete Everything After
    04/05/21 10:32 am ​ HOUSE RESEARCH RC/MV H2128DE1​ 1.1 .................... moves to amend H.F. No. 2128 as follows:​ 1.2 Delete everything after the enacting clause and insert:​ 1.3 "ARTICLE 1​ 1.4 DHS HEALTH CARE PROGRAMS​ 1.5 Section 1. [62A.002] APPLICABILITY OF CHAPTER.​ 1.6 Any benefit or coverage mandate included in this chapter does not apply to managed​ 1.7 care plans or county-based purchasing plans when the plan is providing coverage to state​ 1.8 public health care program enrollees under chapter 256B or 256L.​ 1.9 Sec. 2. Minnesota Statutes 2020, section 62C.01, is amended by adding a subdivision to​ 1.10 read:​ 1.11 Subd. 4. Applicability. Any benefit or coverage mandate included in this chapter does​ 1.12 not apply to managed care plans or county-based purchasing plans when the plan is providing​ 1.13 coverage to state public health care program enrollees under chapter 256B or 256L.​ 1.14 Sec. 3. Minnesota Statutes 2020, section 62D.01, is amended by adding a subdivision to​ 1.15 read:​ 1.16 Subd. 3. Applicability. Any benefit or coverage mandate included in this chapter does​ 1.17 not apply to managed care plans or county-based purchasing plans when the plan is providing​ 1.18 coverage to state public health care program enrollees under chapter 256B or 256L.​ 1.19 Sec. 4. [62J.011] APPLICABILITY OF CHAPTER.​ 1.20 Any benefit or coverage mandate included in this chapter does not apply to managed​ 1.21 care plans or county-based purchasing plans when the plan is providing coverage to state​ 1.22 public health care program enrollees under chapter 256B or 256L.​ Article 1 Sec.
    [Show full text]
  • Emergency Department Requirement for Assessment of Outpatients Who Receive Injectable Narcotics
    This is an Interior Health CONTROLLED document. A copy of this document in paper form is not controlled and should be checked against the electronic file version to ensure accuracy Administrative Policy Manual Code: AH Patient/Client Relations/Care AH0600 - EMERGENCY DEPARTMENT REQUIREMENT FOR ASSESSMENT OF OUTPATIENTS WHO RECEIVE INJECTABLE NARCOTICS 1.0 PURPOSE To promote quality care and patient safety by ensuring Outpatients are appropriately assessed by an EDP or MRP when receiving or prior to receiving an injectable Narcotic in Emergency Departments (ED) of Interior Health (IH). 2.0 DEFINITIONS EDP Emergency Department Physician MRP Most Responsible Physician Narcotic Any substance set out in the schedule or anything that contains any substance set out in the schedule in the (Narcotic Control Regulations, CRC. C., 1041), see Appendix B. Outpatient A patient who presents to the ED for care and is not hospitalized or admitted to hospital. 3.0 POLICY 3.1 Assessment and Order Required This policy applies to Narcotic injection(s) administered to Outpatients being treated for acute and/or chronic conditions at IH EDs. Narcotic injection(s) will only be administered to Outpatients when the Outpatient has been assessed by an EDP/MRP (with active privileges in the administering facility) and the EDP/MRP has written an order dated within 24 hours of the Narcotic injection being administered. NOTE: Phone orders are acceptable on the undertaking the EDP/MRP will assess the Outpatient within 24 hours of the phone order. Orders for a series of Narcotic injections in excess of 24 hours require Outpatients be reassessed by an EDP/MRP (with active privileges in the administering facility) within 24 hours of the initial order and within every 24 hours thereafter while the Narcotic injection order is in effect.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Narcotic Drugs and Psychotropic Substances (Control) Act
    LAWS OF GUYANA Narcotic Drugs and Psychotropic Cap. 35:11 3 Substances (Control) CHAPTER 35:11 NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES (CONTROL) ACT ARRANGEMENT OF SECTIONS PART I PRELIMINARY SECTION 1. Short title. 2. Interpretation. PART II PROHIBITION OF POSSESSION OF AND TRAFFICKING IN NARCOTICS AND CULTIVATION OF CERTAIN PLANTS 3. Definitions for Part II. 4. Penalty for possession of narcotic. 5. Penalty for trafficking in narcotic. 6. Penalty for supply, etc., of narcotic to child or young person if death results from consumption or administration of it. 7. Penalty for bringing into prison or taking out of prison, etc., of a narcotic. 8. Penalty for cultivation of certain plants. 9. Procedure for purposes of section 8(2) to (6). 10. Power of entry in respect of State or Government lands. 11. Power of destruction of prohibited plants. 12. Penalty for certain other acts connected with narcotics. 13. Certain prescriptions to be unlawful. 14. Penalty for receiving additional narcotic or prescription without disclosure of earlier receipt. 15. Removal of name from register. L.R.O. 3/1998 LAWS OF GUYANA 4 Cap. 35:11 Narcotic Drugs and Psychotropic Substances (Control) PART III NARCOTICS IN TRANSIT SECTION 16. Definitions for Part III. 17. Prohibition against sending narcotics by post. 18. Narcotics in transit. 19. Control of Comptroller over narcotics brought into Guyana in transit. 20. Tampering with narcotics in transit. 21. Diversion in Guyana of narcotics in transit. 22. Variations in export authorisation, import authorisation or diversion certificate granted in country other than Guyana. PART IV LICENCES 23. Grant and renewal of licences.
    [Show full text]
  • Newer Unregulated Drugs Look-Up Table
    Newer Unregulated Drugs Look-up Table List Name Chemical Name/AKA Type of drug Notes Stimulant Regulation under MDA (Sch. 1 or TCDO) Stimulant/Hallucinogen Regulation under MDA (Sch. 2-5) Hallucinogen Regulated by PSA Depressant Exempt Cannabinoid Uncertain/requires clarification 1P-LSD 1-propionyl-lysergic acid diethylamide Hallucinogen An LSD analogue that side-stepped MDA and was on sale as an NPS; now covered by the PSA. 2-AI 2-Aminoindane Stimulant, amphetamine analogue Reported in the UK in 2011 by the Forensic Early 2-MAI N-methyl-2-Aminoindane Warning System (FEWS). Had been on sale via number MMAI of online stores; covered by PSA. 2-MeO-ketamine Methoxyketamine Related to methoxetamine so a relative Believed to have been made a CD at the same time as Methoxieticyclidine of ketamine – i.e. a dissassociative Methoxetamine anaesthetic hallucinogen 2C-B-BZP (1-(4-bromo-2,5- Piperazine family; stimulant Class B dimethoxybenzyl)piperazine) 2-DPMP Desoxypipadrol stimulant Strong and long acting stimulant; reported duration of 2-diphenylmethylpiperidine effect 24-28hrs or more and effective at very low doses. Had been on sale in the UK and cropped up in branded “Ivory Wave” and in other compounds. Linked to fatalities. Class B, Sch1. 2-NE1 APICA Synthetic cannabinoid receptor agonist 3rd generation SCRA. Covered by PSA SDB-001 N-(1-adamantyl)-1-pentyl-1H-indole-3- carboxamide 3-FPM Phenzacaine Stimulant, euphoriants Sibling of the controlled drug Phenmetrazine. Emerged PAL-593 2015. Covered by PSA 2-(3-fluorophenyl)-3-methylmorpholine 3-hydroxyphenazepam Benzo, GABA-nergic PSA 3-MeO-PCE (3-methoxyeticyclidine) Related to methoxetamine so a relative Probably regulated under the same clause that made of ketamine – i.e.
    [Show full text]
  • Questions & Answers
    SERVING CANADIANS Research and Statistics Division questions & answers February 2003 www.canada.justice.gc.ca/en/ps/rs Drug Use and Offending by: Nathalie Quann, Research Analyst Q1. How has drug legislation changed recently? Table of Contents Q1. How has drug legislation changed recently? .................................................1 Since May 1997, the Controlled Drugs and Substances Act governs all drug offences in Canada. Q2. What are the most recent Canadian statistics on drug use? ............................2 Prior to 1997, the two most important federal statutes dealing with Q3. What is the public attitude towards illicit drugs were the Narcotics Control Act (NCA) and the Food and decriminalization of drugs? ...................4 Drugs Act (FDA). The Narcotics Control Act governed over 120 different types of drugs such as cocaine, heroin, opium, and Q4. What do Canadians think about the cannabis. The NCA did not distinguish one drug from another. For medical use of soft drugs? ......................5 example, cannabis and cocaine offenders were subject to the same Q5. How is the health care system affected criminal procedures and penalties. The Food and Drugs Act governed by drug use and abuse? ..........................5 the regulation of pharmaceutical drugs, food, cosmetics, and medical devices. Two parts most specifically dealt with the non-medical use Q6. How many drug offences were reported of specific drugs: Part III governed "controlled drugs" (such as by the police in 2000? ............................6 amphetamines, barbiturates, testosterone) while Part IV governed Q7. Are offenders always charged by the "restricted drugs" (such as LSD, and other hallucinogenic drugs). police when drugs are involved? ...........7 The maximum penalties were less strict under the FDA than the NCA.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]